TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021005859
Abstract: Steffen Boettcher (University of Zurich and University Hospital Zurich, Switzerland) Roman Schimmer (University of Zurich and University Hospital Zurich, Switzerland) Larisa Kovtonyuk (University of Hospital Zurich and University of Zurich, Switzerland) Nancy Klemm (University of… read more here.
Keywords: university hospital; university; zurich; zurich switzerland ... See more keywords